Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome. (2014)
Attributed to:
MRC Centre for Transplantation
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.bbmt.2013.10.021
PubMed Identifier: 24216184
Publication URI: http://europepmc.org/abstract/MED/24216184
Type: Journal Article/Review
Volume: 20
Parent Publication: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Issue: 1
ISSN: 1083-8791